Light-emitting diode-generated red light inhibits keloid fibroblast proliferation

Andrew Mamalis, Jared Jagdeo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Red light is part of the visible light spectrum that does not generate DNA adducts associated with skin cancer and photoaging and may represent a safer therapeutic modality for treatment of keloid scars and other fibrotic skin diseases. Our laboratory previously demonstrated that light-emitting diode-generated red light (LED-RL) inhibits proliferation of skin fibroblasts. The effects of LED-RL on keloidal skin are not well characterized. Objective: To determine the effect of LED-RL on keloid-derived fibroblast proliferation and viability in vitro. METHODS: Irradiation of primary keloid-derived human skin fibroblasts using LED-RL panels was performed in vitro, and modulation of proliferation and viability was quantified using trypan blue dye exclusion assay. Statistical analysis was performed using analysis of variance to compare treatment arms and the Student t-test to compare each treatment arm with the paired bench control arm. Results: Keloid fibroblasts treated with LED-RL 240, 320, and 480 J/cm demonstrated statistically significant dose-dependent decreases in relative proliferation rate of 12.4%, 16.5%, and 28.9%, respectively, compared with matched nonirradiated controls (p <.05) and did not significantly alter viability relative to the matched nonirradiated controls. Conclusion: Light-emitting diode-generated red light can inhibit keloid fibroblast proliferation in a dose-dependent manner without altering viability. Light-emitting diode-generated red light has the potential to contribute to the treatment of keloids and other fibrotic skin diseases and is worthy of further translational and clinical investigation.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalDermatologic Surgery
Volume41
Issue number1
DOIs
StatePublished - Jan 13 2015

Fingerprint

Keloid
Fibroblasts
Light
Skin Diseases
Skin
Therapeutics
Trypan Blue
DNA Adducts
Skin Neoplasms

ASJC Scopus subject areas

  • Dermatology
  • Surgery
  • Medicine(all)

Cite this

Light-emitting diode-generated red light inhibits keloid fibroblast proliferation. / Mamalis, Andrew; Jagdeo, Jared.

In: Dermatologic Surgery, Vol. 41, No. 1, 13.01.2015, p. 35-39.

Research output: Contribution to journalArticle

@article{34415711fda7488cb61e2b19b9666992,
title = "Light-emitting diode-generated red light inhibits keloid fibroblast proliferation",
abstract = "Background: Red light is part of the visible light spectrum that does not generate DNA adducts associated with skin cancer and photoaging and may represent a safer therapeutic modality for treatment of keloid scars and other fibrotic skin diseases. Our laboratory previously demonstrated that light-emitting diode-generated red light (LED-RL) inhibits proliferation of skin fibroblasts. The effects of LED-RL on keloidal skin are not well characterized. Objective: To determine the effect of LED-RL on keloid-derived fibroblast proliferation and viability in vitro. METHODS: Irradiation of primary keloid-derived human skin fibroblasts using LED-RL panels was performed in vitro, and modulation of proliferation and viability was quantified using trypan blue dye exclusion assay. Statistical analysis was performed using analysis of variance to compare treatment arms and the Student t-test to compare each treatment arm with the paired bench control arm. Results: Keloid fibroblasts treated with LED-RL 240, 320, and 480 J/cm demonstrated statistically significant dose-dependent decreases in relative proliferation rate of 12.4{\%}, 16.5{\%}, and 28.9{\%}, respectively, compared with matched nonirradiated controls (p <.05) and did not significantly alter viability relative to the matched nonirradiated controls. Conclusion: Light-emitting diode-generated red light can inhibit keloid fibroblast proliferation in a dose-dependent manner without altering viability. Light-emitting diode-generated red light has the potential to contribute to the treatment of keloids and other fibrotic skin diseases and is worthy of further translational and clinical investigation.",
author = "Andrew Mamalis and Jared Jagdeo",
year = "2015",
month = "1",
day = "13",
doi = "10.1097/01.DSS.0000452650.06765.51",
language = "English (US)",
volume = "41",
pages = "35--39",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Light-emitting diode-generated red light inhibits keloid fibroblast proliferation

AU - Mamalis, Andrew

AU - Jagdeo, Jared

PY - 2015/1/13

Y1 - 2015/1/13

N2 - Background: Red light is part of the visible light spectrum that does not generate DNA adducts associated with skin cancer and photoaging and may represent a safer therapeutic modality for treatment of keloid scars and other fibrotic skin diseases. Our laboratory previously demonstrated that light-emitting diode-generated red light (LED-RL) inhibits proliferation of skin fibroblasts. The effects of LED-RL on keloidal skin are not well characterized. Objective: To determine the effect of LED-RL on keloid-derived fibroblast proliferation and viability in vitro. METHODS: Irradiation of primary keloid-derived human skin fibroblasts using LED-RL panels was performed in vitro, and modulation of proliferation and viability was quantified using trypan blue dye exclusion assay. Statistical analysis was performed using analysis of variance to compare treatment arms and the Student t-test to compare each treatment arm with the paired bench control arm. Results: Keloid fibroblasts treated with LED-RL 240, 320, and 480 J/cm demonstrated statistically significant dose-dependent decreases in relative proliferation rate of 12.4%, 16.5%, and 28.9%, respectively, compared with matched nonirradiated controls (p <.05) and did not significantly alter viability relative to the matched nonirradiated controls. Conclusion: Light-emitting diode-generated red light can inhibit keloid fibroblast proliferation in a dose-dependent manner without altering viability. Light-emitting diode-generated red light has the potential to contribute to the treatment of keloids and other fibrotic skin diseases and is worthy of further translational and clinical investigation.

AB - Background: Red light is part of the visible light spectrum that does not generate DNA adducts associated with skin cancer and photoaging and may represent a safer therapeutic modality for treatment of keloid scars and other fibrotic skin diseases. Our laboratory previously demonstrated that light-emitting diode-generated red light (LED-RL) inhibits proliferation of skin fibroblasts. The effects of LED-RL on keloidal skin are not well characterized. Objective: To determine the effect of LED-RL on keloid-derived fibroblast proliferation and viability in vitro. METHODS: Irradiation of primary keloid-derived human skin fibroblasts using LED-RL panels was performed in vitro, and modulation of proliferation and viability was quantified using trypan blue dye exclusion assay. Statistical analysis was performed using analysis of variance to compare treatment arms and the Student t-test to compare each treatment arm with the paired bench control arm. Results: Keloid fibroblasts treated with LED-RL 240, 320, and 480 J/cm demonstrated statistically significant dose-dependent decreases in relative proliferation rate of 12.4%, 16.5%, and 28.9%, respectively, compared with matched nonirradiated controls (p <.05) and did not significantly alter viability relative to the matched nonirradiated controls. Conclusion: Light-emitting diode-generated red light can inhibit keloid fibroblast proliferation in a dose-dependent manner without altering viability. Light-emitting diode-generated red light has the potential to contribute to the treatment of keloids and other fibrotic skin diseases and is worthy of further translational and clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=84920815620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920815620&partnerID=8YFLogxK

U2 - 10.1097/01.DSS.0000452650.06765.51

DO - 10.1097/01.DSS.0000452650.06765.51

M3 - Article

VL - 41

SP - 35

EP - 39

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 1

ER -